iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
Form 4 overview: iRhythm Technologies (IRTC) Chief Financial Officer Daniel G. Wilson disclosed the sale of 3,000 common shares on 06/23/2025 at $150 per share, generating approximately $450,000 in proceeds.
Remaining ownership: After the transaction, Wilson directly owns 40,307 shares. No indirect holdings were reported.
Trade context: The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 11/14/2024, which can shield the insider from accusations of timing the market.
No derivative activity: Table II shows no option exercises, grants, or other derivative movements.
Investor takeaways: Insider sales can raise questions about management’s confidence, but the modest size relative to Wilson’s remaining stake and the pre-planned nature reduce negative interpretation. The transaction does not affect the company’s capital structure or operations but provides incremental insight into insider sentiment toward IRTC’s valuation around the $150 level.
iRhythm Technologies, Inc. (NASDAQ: IRTC) – Form 144 filing overview
On the latest Form 144 notice, insider Daniel Wilson has disclosed a proposed sale of 3,000 common shares of iRhythm Technologies. The sale will be executed through Morgan Stanley Smith Barney LLC on or about 23 June 2025. Based on the filing’s stated price, the transaction is valued at approximately $450,000.
iRhythm reports 31,925,267 shares outstanding; the proposed sale therefore equals roughly 0.009 % of the company’s issued shares. The shares being sold were originally acquired via company equity awards: 1,063 performance shares (27 Feb 2023), 970 restricted shares (1 Mar 2023) and 967 performance shares (27 Feb 2024).
The filing also lists insider sales during the previous three months: on 2 May 2025, Wilson sold 333 and 1,667 common shares for total gross proceeds of $250,000. The Form 144 certification states that the seller affirms no knowledge of undisclosed material adverse information at the time of filing.
Because the notice covers a relatively small portion of total shares outstanding and does not introduce new corporate information, the immediate market impact is expected to be limited; nevertheless, investors often track insider activity for signalling purposes.
iRhythm Technologies (NASDAQ: IRTC) has filed a Form 144 notice for a proposed sale of securities by an insider. The filing details planned sales of 936 shares of common stock with an aggregate market value of $140,400, to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around June 23, 2025.
The securities were originally acquired as Restricted Stock from the issuer on March 1, 2025. The selling party, Chad Patterson, has conducted several previous transactions in the past 3 months totaling:
- 363 shares sold on June 10, 2025 ($54,450)
- 8,510 shares sold on May 2, 2025 ($1,025,897.50)
The total outstanding shares of iRhythm Technologies are reported at 31,925,267. This Form 144 filing indicates the seller's representation that they are not aware of any material adverse non-public information regarding the company's operations.